Analyst Ratings for [HSIC] Henry Schein, Inc.

7/25/25	Downgrades	Buy Hold	X
HSIC Henry Schein Stifel
$75
7/14/25	Downgrades	Outperform Neutral	X
HSIC Henry Schein Robert W. Baird
$72
2/14/25	Initiated	Equal Weight	X
HSIC Henry Schein Wells Fargo
$80
1/6/25	Upgrades	Underperform Buy	X
HSIC Henry Schein BofA Securities
$69 $84
12/4/24	Initiated	Neutral	X
HSIC Henry Schein Mizuho
$75
7/22/24	Upgrades	Neutral Outperform	X
HSIC Henry Schein Robert W. Baird
$81 $92
2/26/24	Initiated	Market Perform	X
HSIC Henry Schein Leerink Partners
$78
12/12/23	Upgrades	Neutral Overweight	X
HSIC Henry Schein JP Morgan
$71 $82
11/10/23	Upgrades	Hold Buy	X
HSIC Henry Schein Stifel
$70
8/8/22	Upgrades	Sell Neutral	X
HSIC Henry Schein UBS
$80
6/14/22	Downgrades	Outperform Neutral	X
HSIC Henry Schein Robert W. Baird
$103 $88
5/13/22	Resumed	Outperform	X
HSIC Henry Schein Credit Suisse
$100
1/7/22	Upgrades	Neutral Outperform	X
HSIC Henry Schein Credit Suisse
$78 $90
10/1/21	Resumed	Neutral	X
HSIC Henry Schein Credit Suisse
$78
2/8/21	Resumed	Overweight	X
HSIC Henry Schein Piper Sandler
$83
1/4/21	Upgrades	Neutral Outperform	X
HSIC Henry Schein Robert W. Baird
$70 $79
8/7/19	Downgrades	Outperform Mkt Perform	X
HSIC Henry Schein William Blair
5/30/19	Initiated	Underperform	X
HSIC Henry Schein Wolfe Research
5/15/19	Downgrades	Outperform Mkt Perform	X
HSIC Henry Schein SVB Leerink
$75 $70
4/18/19	Initiated	Buy	X
HSIC Henry Schein Guggenheim
1/17/19	Initiated	Sell	X
HSIC Henry Schein UBS
$73
1/3/19	Downgrades	In-line Underperform	X
HSIC Henry Schein Evercore ISI
1/2/19	Downgrades	Outperform Neutral	X
HSIC Henry Schein Robert W. Baird
11/8/18	Reiterated	Outperform	X
HSIC Henry Schein Barrington Research
$92 $96
10/25/18	Downgrades	Hold Sell	X
HSIC Henry Schein Edward Jones
10/19/18	Resumed	Neutral	X
HSIC Henry Schein Goldman
10/4/18	Reiterated	Outperform	X
HSIC Henry Schein Robert W. Baird
$90 $95
8/7/18	Reiterated	Hold	X
HSIC Henry Schein Stifel
$76 $81
4/24/18	Downgrades	Buy Neutral	X
HSIC Henry Schein Goldman
4/4/18	Upgrades	Mkt Perform Outperform	X
HSIC Henry Schein Leerink Partners
3/8/18	Initiated	Equal Weight	X
HSIC Henry Schein Barclays
$71
2/27/18	Resumed	Neutral	X
HSIC Henry Schein BofA/Merrill
2/20/18	Downgrades	Outperform In-line	X
HSIC Henry Schein Evercore ISI
2/15/18	Resumed	Neutral	X
HSIC Henry Schein JP Morgan
$77

HSIC Henry Schein, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Henry Schein, Inc. is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. The technology and value-added services segment provides software, technology and other value-added services to healthcare practitioners. Its technology group offerings include practice management software systems for dental and medical practitioners and animal health clinics. The Company provides its services to dental practitioners and laboratories, animal health clinics and physician practices, as well as government and institutional healthcare clinics.